Sermorelin Side Effects and Safety: What to Monitor

Key takeaways

• Sermorelin's documented side effects are mostly local and mild. On the former FDA label, based on 350 patients (children), injection-site pain, swelling or redness affected about 1 in 6 and only 3 stopped; headache, flushing, dizziness and hives each occurred in under 1%.
• In adults, the longest trial (16 weeks, 19 people aged 55 to 71, a closely related GHRH analog) found one adverse effect: a transient rise in blood lipids that resolved. Shorter trials found no significant adverse effects and no change in fasting glucose.
• The larger questions come from raising growth hormone and IGF-1: fluid retention, joint pain, carpal tunnel symptoms and higher blood sugar, documented for growth hormone itself and on the label of tesamorelin, a related drug, but never measured in a large sermorelin trial in adults.
• Do not use it with an active or recent cancer, in pregnancy or breastfeeding, or with a known allergy to it. Untreated hypothyroidism and glucocorticoids blunt the response; uncontrolled diabetes or retinopathy calls for a specialist.
• Monitor IGF-1 and fasting glucose or HbA1c before starting and at 8 to 12 weeks, then every 3 to 6 months, plus thyroid function, which the former label required. Stop if IGF-1 runs high, glucose rises, or swelling, numbness or allergic signs appear.

Sermorelin peptide side effects are usually mild and local: injection-site pain, swelling or redness, which affected about 1 in 6 patients on the former FDA label, plus occasional flushing, headache and dizziness. The longer-term concerns are those of raising growth hormone and IGF-1 (fluid retention, joint pain, carpal tunnel symptoms, higher blood sugar), and the longest adult trial reported a transient rise in blood lipids. This page is part of our peptide side effects guide; compare BPC-157 side effects, a peptide with almost no human safety data. For what sermorelin does and how it is dosed, see the sermorelin profile and the sermorelin dosage chart.

Sermorelin side effects: what each source reports

Sermorelin was approved as Geref for children with growth hormone deficiency and withdrawn in 2008 for commercial reasons, so the only side-effect rates come from that pediatric program. The adult trials were small and short.

Two cautions in reading it. The rates are from children, whose growth hormone deficiency and dosing (30 mcg/kg a night) differ from adult wellness use. And the 16-week trial used [Nle27]GHRH(1-29)-NH2, a version of sermorelin with one amino acid changed for stability; its results support sermorelin but are not identical to it (Khorram 1997).

The growth hormone and IGF-1 concerns

Sermorelin works by making your pituitary release more of its own growth hormone, which raises IGF-1. Its theoretical long-term risks are therefore those of growth hormone. In a systematic review of growth hormone given to healthy older adults, treated people were significantly more likely to have soft-tissue edema, joint pain, carpal tunnel syndrome and breast enlargement in men, and somewhat more likely to develop diabetes or impaired fasting glucose (Liu 2007). Sermorelin should produce less of this: it is cleared within minutes, produces a pulse rather than a constant level, and leaves the feedback loops that cap growth hormone output intact. A review of secretagogue trials found the class generally well tolerated, with blood glucose as the consistent concern, and noted that cancer incidence and mortality with long-term use have never been evaluated (Sigalos 2018).

The closest labeled numbers come from tesamorelin, a stabilized GHRH analog acting on the same receptor. Over 26 weeks, peripheral edema occurred in 6% versus 2% on placebo, joint pain in 13% versus 11%, tingling in 5% versus 2%, carpal tunnel in 1% versus 0%, and new diabetes (HbA1c of 6.5% or higher) in 5% versus 1%; IGF-1 was more than two standard deviations above normal in 47% (Egrifta WR label 2025). Tesamorelin is a different drug, given at doses that reliably raise IGF-1, so treat these figures as the direction of risk for the class, not as sermorelin's rates.

Three points specific to sermorelin:

• Glucose. Fasting glucose did not change in the 14-day, 6-week or 16-week adult trials, and insulin sensitivity improved in men in the longest one (Khorram 1997). Reassuring, but those trials were small; it is measured rather than assumed.
• Lipids. The only adverse effect in the 16-week trial was transient hyperlipidemia, which resolved by the end (Khorram 1997); the 6-week trial found no lipid change (Vittone 1997).
• Dose. Typical telehealth doses (200 to 500 mcg a night) are below those used in the adult trials, which may mean fewer growth hormone effects, and also less benefit; the sermorelin profile explains the gap.

Who should not use sermorelin

• A known allergy to sermorelin or its ingredients: the former label's only formal contraindication (sermorelin label).
• An active or recent cancer. GH and IGF-1 are growth signals; tesamorelin's label makes active malignancy a contraindication (Egrifta WR label 2025).
• Pregnancy or breastfeeding. The former label placed sermorelin in pregnancy category C and said it is not known whether it enters breast milk; there is no reason to use it then.
• Untreated hypothyroidism. The label warns it can jeopardize the response and asked for thyroid tests before and during treatment; treat the thyroid first.
• Glucocorticoids such as prednisone, which may inhibit the response (sermorelin label).
• Diabetes. Uncontrolled diabetes or diabetic retinopathy calls for a specialist's sign-off, because IGF-1 can worsen retinopathy and growth hormone raises glucose; prediabetes calls for glucose monitoring.
• A pituitary disorder or intracranial mass. Patients whose deficiency came from an intracranial lesion were not studied, and sermorelin needs a working pituitary.

Sermorelin is also prohibited in tested sport; see the sermorelin profile. Women can use it; the sermorelin for women guide covers menopause questions.

What to monitor

The plan is the one in our sermorelin profile, not a published guideline, and the drift in IGF-1 comes from the 16-week trial (Khorram 1997). Because that trial's only adverse effect was a rise in lipids, a baseline lipid panel gives a comparison if one is repeated. There is no sermorelin-specific IGF-1 ceiling; the nearest labeled rule is tesamorelin's, which says to consider stopping when IGF-1 stays above three standard deviations (Egrifta WR label 2025). If you use a compounded vial, check your units with the reconstitution calculator.

When to stop

Talk to the prescriber about stopping or reducing the dose if:

• IGF-1 runs well above the age-adjusted reference range, or has not moved at all after 8 to 12 weeks;
• fasting glucose or HbA1c rises into the prediabetes or diabetes range;
• swelling, joint pain or numbness in the hands persists;
• injection-site reactions keep recurring despite rotating sites (see how to inject peptides).

Stop and get care the same day for hives, swelling of the face or lips, or wheezing (emergency services if breathing is affected), spreading redness or fever after an injection, or a new cancer diagnosis or pregnancy.

Bottom line

Sermorelin's documented side effects are modest: injection-site reactions in about 1 in 6 patients on its former label, other effects under 1%, and a transient lipid rise in the longest adult trial. What has not been measured is years of use in healthy adults, and the risks of raising growth hormone and IGF-1 (fluid retention, joint and nerve symptoms, higher glucose, and caution with cancer) apply in principle. A safe prescription is one with labs before and after, and a prescriber who acts on them.

Frequently asked questions

+−Is sermorelin safe?

In the studies that exist, it was well tolerated. On the former FDA label, based on 350 patients (children with growth hormone deficiency), the main problem was injection-site pain, swelling or redness in about 1 in 6, and only 3 stopped treatment. Small adult trials of up to 16 weeks reported no significant adverse effects apart from a transient rise in blood lipids. What is not known is long-term safety in healthy adults, because no one has studied sermorelin for years, and raising growth hormone and IGF-1 carries known risks that need monitoring.

+−What are the downsides of taking sermorelin?

Daily injections and the site reactions that come with them; occasional flushing, headache or dizziness; and the risks of raising growth hormone and IGF-1, which with growth hormone itself include fluid retention, joint pain, carpal tunnel symptoms and higher blood sugar. It also needs a working pituitary, does less when thyroid function is low or glucocorticoids are taken, and is commonly prescribed at doses below those that changed IGF-1 in trials, so it may do little.

+−Does sermorelin cause water retention or joint pain?

It can in principle, because these are growth hormone effects, but no sermorelin trial has measured them. In healthy older people given growth hormone itself, edema and joint pain were significantly more common than without it, and on the label of tesamorelin, a related GHRH analog, peripheral edema occurred in 6 percent versus 2 percent on placebo and joint pain in 13 percent versus 11 percent. Sermorelin's short action and intact feedback should make this less likely, but that has not been tested.

+−Does sermorelin raise blood sugar?

In the small adult trials it did not: fasting glucose was unchanged after 14 days, 6 weeks and 16 weeks, and insulin sensitivity improved in men in the 16-week trial. But growth hormone raises the risk of impaired fasting glucose and diabetes, secretagogue reviews flag glucose as the consistent concern, and on the tesamorelin label new diabetes occurred in 5 percent versus 1 percent. That is why fasting glucose or HbA1c belongs in the baseline and follow-up labs.

+−Can sermorelin cause cancer?

There is no evidence that it does, and no study long enough to show it either way. The concern is that growth hormone and IGF-1 are growth signals, which is why an active or recent cancer is a reason not to use sermorelin and why the related drug tesamorelin lists active malignancy as a contraindication. A review of growth hormone secretagogues noted that cancer incidence and mortality with long-term use have never been evaluated.

+−What labs should be checked on sermorelin?

A reasonable plan, from our sermorelin profile: IGF-1, fasting glucose or HbA1c and a basic metabolic panel before starting; IGF-1 and glucose again at 8 to 12 weeks; then every 3 to 6 months. The former label also asked for thyroid tests before and during treatment, because untreated hypothyroidism blunts the response. A clinician who prescribes sermorelin without ever measuring IGF-1 cannot tell whether it is working or running too high.

+−Can women take sermorelin?

Yes. The 16-week adult trial enrolled 10 women and 9 men, growth hormone and IGF-1 rose in both, and the only adverse effect was a transient rise in lipids. Some benefits, such as lean mass and insulin sensitivity, appeared only in men. Sermorelin should not be used in pregnancy or while breastfeeding; the former label placed it in pregnancy category C and said it is not known whether it passes into breast milk.

Sources

1. LabelSermorelin acetate for injection (the former Geref product): prescribing information, FDA revision dated October 2, 2001, side effects, precautions and drug interactions sections, as reproduced by RxList. The brand was withdrawn in 2008 and its label is not on DailyMed. (2001)
2. ReviewPrakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs 1999;12:139-57. (1999)
3. StudyKhorram O, Laughlin GA, Yen SS. Endocrine and metabolic effects of long-term administration of [Nle27]GHRH-(1-29)-NH2 in age-advanced men and women. J Clin Endocrinol Metab 1997;82:1472-9. (1997)
4. StudyVittone J et al. Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men. Metabolism 1997;46:89-96. (1997)
5. StudyCorpas E et al. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and IGF-I levels in old men. J Clin Endocrinol Metab 1992;75:530-5. (1992)
6. ReviewLiu H et al. Systematic review: the safety and efficacy of growth hormone in the healthy elderly. Ann Intern Med 2007;146:104-15. (2007)
7. ReviewSigalos JT, Pastuszak AW. The safety and efficacy of growth hormone secretagogues. Sex Med Rev 2018;6:45-53. (2018)
8. LabelTheratechnologies. EGRIFTA WR (tesamorelin) for injection: prescribing information, revised March 2025 (sections 4, 5 and 6; Table 1). DailyMed. (Egrifta WR label 2025) (2025)